Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.600 enrolled

Overview

The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

600

Conditions

Urinary Incontinence

Interventions

tolterodine SR, overactive bladderDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years or older patients suffering from OAB symptoms (urinary frequency of at least 8 micturitions per 24h, urinary urgency and at least 3 urge urinary incontinence episodes within 3 days), confirmed by a micturition bladder diary. Exclusion Criteria: * Other than urge incontinence * History of prostate/uterine or other female organ cancer

Outcomes

Primary Outcomes

Patient Perception of Bladder Condition at 12 weeks of treatment compared to placebo.

Secondary Outcomes

Other safety and efficacy measures at 12 weeks of treatment.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.